Author

Jessica St. Peter

Observed name: J. Peter

Observed institutions: University of Iowa, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, Moffitt Cancer Center, University of Alabama at Birmingham, Hospices Civils de Lyon, Dana-Farber Cancer Institute, Novartis (United States), The Ohio State University

OpenAlex ID: A5081915656

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

2009 · James C. Yao, Catherine Lombard-Bohas, et al. · Journal of Clinical Oncology · 649

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

2011 · James C. Yao, Marianne Pavel, et al. · The Journal of Clinical Endocrinology & Metabolism · 225

Prognostic and Predictive Value of Chromogranin a and Neuron-specific Enolase in Patients (pts) With Advanced Pancreatic Neuroendocrine Tumors (pnet) Treated With Everolimus

2010 · Kjell Öberg, Michael Kulke, et al. · Annals of Oncology · 13

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy

2010 · James C. Yao, Catherine Lombard-Bohas, et al. · Pancreas · 2

Works count: 5

Citation count: 889

H-index: 3

I10-index: 3